Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Capturing breast cancers’ copy-number landscape in routine pathology : Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond

Kramer, C. J.H. ; van Wijk, L. M. ; Ruano, D. ; Gelpke-Vermeulen, S. ; van der Tuin, K. ; van der Stoep, N. ; van Wezel, T. ; Wesseling, J. ; Vallon-Christersson, J. LU orcid and Smit, V. T.H.B.M. , et al. (2025) In British Journal of Cancer 133(8). p.1199-1207
Abstract

Background: Because breast cancer (BC) is molecularly heterogeneous, diagnosis and treatment will likely benefit from comprehensive genetic profiling. However, routine, high-resolution sequencing is not feasible yet, due to implementation challenges associated with whole-genome sequencing of formalin-fixed paraffin embedded (FFPE) BC samples. Therefore, we explored the potential of an alternative low-resolution, genome-wide testing approach that is able to capture the copy number (CN) landscape, including actionable alterations, in FFPE derived DNA. Methods: The performance of the genome-wide CN testing approach, including CN signatures/focal CN alterations, was evaluated in two phases: (i) exploration and (ii) feasibility phase. First,... (More)

Background: Because breast cancer (BC) is molecularly heterogeneous, diagnosis and treatment will likely benefit from comprehensive genetic profiling. However, routine, high-resolution sequencing is not feasible yet, due to implementation challenges associated with whole-genome sequencing of formalin-fixed paraffin embedded (FFPE) BC samples. Therefore, we explored the potential of an alternative low-resolution, genome-wide testing approach that is able to capture the copy number (CN) landscape, including actionable alterations, in FFPE derived DNA. Methods: The performance of the genome-wide CN testing approach, including CN signatures/focal CN alterations, was evaluated in two phases: (i) exploration and (ii) feasibility phase. First, high-resolution sequencing data of a previously published triple-negative BC cohort (n = 237) was leveraged to benchmark the homologous recombination deficiency (HRD)-related CN signature using a comprehensive, multimodal approach incorporating both genetic and functional HRD tests. Secondly, the low-resolution testing strategy’s feasibility was prospectively evaluated in a BC cohort of patients referred to clinical genetic services (n = 147). Results: Applying the HRD threshold that was established using both genomic and functional HRD data, we identified a 100% sensitivity for BC with BRCA1/BRCA2/PALB2 pathogenic variants in the prospective cohort. Moreover, the success rate of the low-resolution testing approach proved high, regardless of input material. Finally, additional CN alterations were enriched in the HR-proficient BC population, indicating potential actionable CN-alterations beyond HRD. Conclusions: In conclusion, low-resolution, genome-wide sequencing has shown high potential in capturing the CN landscape, including features associated with HRD, in BC patients. This preselection testing approach is likely to maximize potential for personalized medicine and genetic counseling.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
133
issue
8
pages
9 pages
publisher
Nature Publishing Group
external identifiers
  • pmid:40849357
  • scopus:105013809312
ISSN
0007-0920
DOI
10.1038/s41416-025-03134-x
language
English
LU publication?
yes
id
9db28009-db3f-4ef6-a6f7-e5aece2cd195
date added to LUP
2025-11-17 14:45:40
date last changed
2025-11-18 03:22:15
@article{9db28009-db3f-4ef6-a6f7-e5aece2cd195,
  abstract     = {{<p>Background: Because breast cancer (BC) is molecularly heterogeneous, diagnosis and treatment will likely benefit from comprehensive genetic profiling. However, routine, high-resolution sequencing is not feasible yet, due to implementation challenges associated with whole-genome sequencing of formalin-fixed paraffin embedded (FFPE) BC samples. Therefore, we explored the potential of an alternative low-resolution, genome-wide testing approach that is able to capture the copy number (CN) landscape, including actionable alterations, in FFPE derived DNA. Methods: The performance of the genome-wide CN testing approach, including CN signatures/focal CN alterations, was evaluated in two phases: (i) exploration and (ii) feasibility phase. First, high-resolution sequencing data of a previously published triple-negative BC cohort (n = 237) was leveraged to benchmark the homologous recombination deficiency (HRD)-related CN signature using a comprehensive, multimodal approach incorporating both genetic and functional HRD tests. Secondly, the low-resolution testing strategy’s feasibility was prospectively evaluated in a BC cohort of patients referred to clinical genetic services (n = 147). Results: Applying the HRD threshold that was established using both genomic and functional HRD data, we identified a 100% sensitivity for BC with BRCA1/BRCA2/PALB2 pathogenic variants in the prospective cohort. Moreover, the success rate of the low-resolution testing approach proved high, regardless of input material. Finally, additional CN alterations were enriched in the HR-proficient BC population, indicating potential actionable CN-alterations beyond HRD. Conclusions: In conclusion, low-resolution, genome-wide sequencing has shown high potential in capturing the CN landscape, including features associated with HRD, in BC patients. This preselection testing approach is likely to maximize potential for personalized medicine and genetic counseling.</p>}},
  author       = {{Kramer, C. J.H. and van Wijk, L. M. and Ruano, D. and Gelpke-Vermeulen, S. and van der Tuin, K. and van der Stoep, N. and van Wezel, T. and Wesseling, J. and Vallon-Christersson, J. and Smit, V. T.H.B.M. and Cohen, D. and Vrieling, H. and Staaf, J. and Bosse, T. and van Asperen, C. J. and Vreeswijk, M. P.G.}},
  issn         = {{0007-0920}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{1199--1207}},
  publisher    = {{Nature Publishing Group}},
  series       = {{British Journal of Cancer}},
  title        = {{Capturing breast cancers’ copy-number landscape in routine pathology : Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond}},
  url          = {{http://dx.doi.org/10.1038/s41416-025-03134-x}},
  doi          = {{10.1038/s41416-025-03134-x}},
  volume       = {{133}},
  year         = {{2025}},
}